SVRA - NASDAQ
Savara Inc.
$5.25
+1.9%Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
At a Glance
Live SnapshotSavara Inc. Management Team
Mr. Matthew Pauls J.D., M.B.A.
Chairman & Chief Executive Officer
Compensation
$979,000
Ms. Anne Erickson
Chief Business Officer
Mr. David L. Lowrance CPA
Chief Financial Officer, Chief Administrative Officer & Secretary
Compensation
$673,291
Ms. Kate McCabe J.D.
Chief Legal Officer
Dr. Raymond Dennis Pratt FACP, M.D.
Chief Medical Officer
Compensation
$91,889
Mr. Robert Matthew Lutz M.B.A.
Chief Operating Officer
Compensation
$672,451
Mr. Charles LaPree
Executive Vice President & Head of Global Regulatory Affairs
Dr. Yasmine Wasfi M.D., Ph.D.
Executive Vice President and Head of Clinical Development & Clinical Operations
Dr. Brian Robinson M.D.
Executive Vice President of Global Medical Affairs
Brian Maurer
Head of Clinical Operations
Savara Inc. Insider Positioning
During the last 12 months, insiders have purchased $99K and sold $121K worth of SVRA shares, resulting in $23K of net selling activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
20.0K
121.22K
-121K
-$121K
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
48.2K
98.57K
0
0.00
+99K
+$99K
Top Buyers
Hawkins Richard J
Director
$99K
Top Sellers
Ramsay David A
Director
$121K
Insider Activity Analysis
Net Insider Sentiment
Slightly bearish with $23K net selling. Selling modestly exceeds buying, which could be routine diversification rather than concern.
Buy/Sell Ratio
Moderately negative ratio. Selling is roughly double the buying, which may be routine or signal caution.
Insider Participation
1 insider buyers and 1 sellers. Equal participation suggests mixed or neutral insider views.
SEC Filings
SVRA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | April 25, 2025 | June 05, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 26, 2024 | June 06, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 28, 2023 | June 08, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 19, 2022 | June 02, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 27, 2021 | June 10, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 15, 2020 | May 27, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 15, 2019 | May 29, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 23, 2018 | June 04, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | September 13, 2017 | October 25, 2017 | 2017 | |
DEF 14A DEF 14A 2016 N/A | April 28, 2016 | June 15, 2016 | 2016 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.